Mirati Therapeutics has announced changes to their executive management team, effective immediately. Mirati continues to accelerate the development of the KRAS and sitravatinib programs ...
Mirati Therapeutics announced a clinical collaboration with Bristol-Myers Squibb Company to evaluate the combination of sitravatinib and nivolumab (OPDIVO)....
Shares in the California-based biotech Mirati Therapuetics plummeted on Monday after the company released disappointing results from their Phase II study of the experimental drug sitravatinib...